Good sleep. How to achieve this?
Obstructive Sleep Apnea Syndrome (OSA) is a common respiratory illness associated with sleep disturbances, snoring, and respiratory failure in a dream for ten or more seconds. Add to this a…

Continue reading →

What is making noise in our ears?
“Ever since I retired and spent most of my time at home, in silence, I had a ringing in my ears. No matter which doctors I went to or what…

Continue reading →

Three analyzes important to the hero
According to surveys, men are much more careless about their health than women. The vast majority of the stronger sex (72%) does not see the point of having to worry…

Continue reading →

How much does prostate cancer cost?

The costs of treating cancer usually exceed insurance coverage … So: the economic burden of prostate cancer alone in Russia amounted to 3.7 billion rubles a year. These and other important data were the result of a study conducted by the Research Institute of Clinical and Economic Expertise and Pharmaceutical Economics of the Russian National Research Medical University named after Pirogov.

Prostate cancer (PCa) is one of the most commonly diagnosed oncological diseases in the male population of Russia. Over the past ten years, there has been an increase in the incidence and mortality rates from this disease. So, prostate cancer ranks third (11% of the total) in the structure of the primary incidence of malignant neoplasms. In the period from 2000 to 2010. a high rate of increase in the incidence of prostate cancer was noted – an average of 9.83% per year. According to 2010 data, there is a continuation of the growth trend in mortality rates from prostate cancer – compared with 2009, mortality from prostate cancer increased by 2.1%.

Reference: Prostate cancer is a malignant neoplasm that occurs in men, mainly middle-aged and elderly. An important role in the development of the disease is played by androgens – male sex hormones that can contribute to tumor growth.

Reference: Prostate cancer is a malignant neoplasm that occurs in men, mainly middle-aged and elderly. An important role in the development of the disease is played by androgens – male sex hormones that can contribute to tumor growth.

The main risk factors for prostate cancer are age, family history, and ethnicity. Also, risk factors may include nutritional characteristics, but these data today do not have accurate confirmation.

A study of the socio-economic burden of prostate cancer suggests that the total cost of treating all patients with this disease is 3,674,032,748 rubles. The average cost per patient per year is at 33,270 rubles. At the same time, the main volume of expenses falls on patients with an initially established diagnosis, and the costs of treating patients in the late stages of the disease are 6 times lower. This suggests that in order to increase the effectiveness of therapy and reduce the level of mortality from prostate cancer, it is necessary to treat patients at all stages of the disease, which will increase their life expectancy in general.

Despite the fact that the disease occurs mainly in elderly men, late diagnosis, high morbidity and mortality lead to a decrease in the contribution of the economically active population to GDP, since, according to statistics, on average in Russia 34.4% of people continue to work after reaching retirement age.

When considering prostate cancer from the point of view of the economic burden for the state, it is also worth noting that until recently there were no standard approaches to treating patients with a progressive form of this disease, which could significantly increase survival and improve the quality of life of patients.

Recent studies of the biology of metastatic hormone-resistant prostate cancer have led to the development of innovative effective drugs that cope with this task. Such drugs were registered in Russia in 2011 – 2012 and are already used in patients with disease progression during or after chemotherapy. From the point of view of pharmacoeconomic analysis, the costs of such treatment are comparable to the state expenses for other targeted oncological drugs. The use of new drugs for the treatment of prostate cancer in widespread clinical practice will reduce mortality rates, as happened in the recent past with hematologic diseases, lung and breast cancer.

“Pharmacoeconomic analysis showed that the cost of a patient’s saved year of life when using new drugs registered in Russia today is comparable to the same costs of drugs already included in the list of vital drugs. This suggests the acceptability of using such therapy for the healthcare system of the Russian Federation,” – commented Elena Derkach, senior researcher at the Laboratory for Clinical and Economic Analysis, Research Institute of Clinical and Economic Expertise and Pharmacoeconomics, Russian State Medical University.

Migraine changes its character
Women are initially more prone to headaches. They are 3-4 times more likely than men to suffer from it. According to experts, female migraine changes its character - now attacks…

...

How much does prostate cancer cost?
The costs of treating cancer usually exceed insurance coverage ... So: the economic burden of prostate cancer alone in Russia amounted to 3.7 billion rubles a year. These and other…

...

Who has an extra chord in his heart
Do not be alarmed! Everyone should have a chord in their hearts. The only question is its quality. A normal chord in the heart is a fibrous tissue resembling a…

...

Diagnostics in the regions: figures, facts and money
Recently, in Moscow, the IMEDA Association held a meeting on the topic "Modern diagnostics and (un) health of Russians." The event was timed to coincide with the release of the…

...